UA-45667900-1

Thursday, 15 January 2026

Brain repair, protection, or optimization: what is biologically possible in level 3 autisms?

 


Piano tuning vs Brain tuning


Discussions about brain repair often mix together very different biological processes. This leads to confusion, unrealistic expectations, and unhelpful metaphors—most notably the idea that autism reflects “miswired” brains that must somehow be rewired. A more useful approach is to distinguish between construction, protection, repair, and optimization, and to recognise that each dominates at different stages of life and in different conditions.

This discussion focuses primarily on level 3 autism, where early developmental vulnerability, high support needs, and biological stressors play a central role in shaping long-term outcome.

 

Why “brain wiring” is a misleading analogy — and why fine-tuning is better

Autism is frequently described using the language of wiring: faulty circuits, miswired connections, or incorrect neural networks. While intuitively appealing to some, this metaphor is biologically misleading and ultimately unhelpful when discussing development, intervention, or long-term outcome.

The brain does not contain fixed wires. Neurons are living cells embedded in a biochemical, metabolic, and immunological environment that is in constant flux. Synapses strengthen and weaken, receptors are trafficked in and out of membranes, ion gradients shift, myelination adapts to activity, and neuromodulators continuously reshape how information is processed. Even in adulthood, neural networks are not static structures but dynamic systems.

The problem with the wiring metaphor is not that it is entirely wrong, but that it implies permanence and rigidity. Wires, once laid incorrectly, must be physically replaced. This framing naturally leads either to pessimism (“the brain is miswired and cannot be fixed”) or to unrealistic repair narratives (“we must rewire it”). Neither reflects how brains actually function.

A more accurate analogy is fine-tuning or calibration.

In many forms of autism—particularly outside of early severe neuronal loss—the core issue is not missing connections, but suboptimal parameter settings within otherwise intact networks. These include excitatory–inhibitory balance, timing and synchrony, sensory gain control, neuromodulatory tone, and signal-to-noise ratios. These parameters are continuously adjustable across the lifespan.

Fine-tuning implies adjustment rather than reconstruction, optimization rather than replacement. It explains why meaningful improvement remains possible in adulthood, while also acknowledging that early developmental constraints can limit what is achievable later.

In level 3 autism, early neuronal loss or failure of maturation can impose hard structural constraints. In such cases, fine-tuning cannot recreate missing cell populations or replay early construction. But even here, the remaining networks still require calibration. Early protection raises the ceiling; later tuning determines how close that ceiling is reached.

This distinction underlies the rest of this discussion.

 

Neuroblasts: builders, not repair workers

Neuroblasts play a central role during early development. They generate neuronal populations, migrate to appropriate regions, and differentiate into specific cell types. In doing so, they establish the cellular and developmental context in which later plasticity operates.

Outside of development, however, their role is limited. In adulthood, neuroblast generation is sparse and restricted to specific niches, and their contribution to functional recovery after injury (such as stroke) is modest and local. Neuroblasts are therefore best understood as developmental builders, not as the primary agents of ongoing brain repair or optimization.

This distinction matters, because many neurodevelopmental conditions arise from a developmental vulnerability during periods of rapid growth and high metabolic demand.

 

Early vulnerability, degeneration, and plateau

Several severe neurodevelopmental disorders share a common pattern: early disruption or selective neuronal loss followed by long-term stability rather than ongoing degeneration.

Examples include Rett syndrome, CASK-related disorders, certain mitochondrial diseases, and some forms of regressive autism. In these conditions, neurons are lost or fail to mature during early life, when metabolic demand is high and protective systems are immature. Once development slows, the system stabilises and a plateau is reached.

This pattern is often misinterpreted as neurodegeneration. In reality, it reflects failure to complete development under stress, not a progressive destructive process.

 

Mild autism: intact structure, altered tuning

In contrast, many individuals diagnosed with milder forms of autism show preserved gross brain structure, intact cellular populations, and no widespread neuronal loss. Here, the challenge is not repair in the sense of replacing lost neurons, but optimization—particularly of inhibitory timing, neuromodulatory balance, sensory gain control, and network signal-to-noise.

Because the underlying structure is intact, interventions can remain effective across the lifespan without implying reconstruction of early development.

 

The problem with an ever-broadening autism spectrum

The autism spectrum has value as a descriptive and administrative category. However, as it has broadened, it has become increasingly biologically heterogeneous. Conditions with very different mechanisms, trajectories, and therapeutic constraints are now grouped under a single label.

 

Why timing matters in level 3 autism

In level 3 autism, timing is as important as mechanism. This group is enriched for syndromic, regressive, epileptic, and metabolically vulnerable forms of autism, all of which place exceptional stress on the developing brain. Early life combines high energetic demand with immature antioxidant defenses, immune regulation, and microglial control.

For this reason, the earlier developmental stress is reduced, the better the long-term functional ceiling is likely to be. Interventions that reduce oxidative stress, dampen maladaptive neuroinflammation, support mitochondrial function, and stabilize microglial behavior are most likely to have their greatest impact when introduced early—before cumulative stress fixes a lower developmental plateau.

The goal is not to reverse development or guarantee recovery, but to preserve functional substrate. Earlier protection raises the ceiling for later fine-tuning.

 

How developmental stress leads to neuronal loss

In level 3 autism, neuronal loss is not random and not degenerative in the adult sense. It reflects convergence of several stress-driven mechanisms.

 

·        Calcium dysregulation

Excess calcium influx via NMDA receptors and voltage-gated channels overwhelms immature buffering systems, disrupts mitochondria, activates destructive enzymes, and triggers apoptotic pathways.

·        Mitochondrial failure

Calcium overload impairs ATP production and increases reactive oxygen species. Falling ATP worsens ion pump failure, reinforcing calcium toxicity.

·        Oxidative stress

Developing neurons have weak antioxidant defenses. Excess ROS damages membranes, ion channels, and DNA, further impairing energy and calcium control.

 

·        Neuroinflammation and microglia

Microglia guide normal synaptic pruning, but under inflammatory conditions they amplify excitotoxicity and misdirect refinement. Even low-grade, episodic inflammation during critical windows can have lasting effects.


Why loss plateaus

These mechanisms are most dangerous during early development. Once growth slows and protective capacity improves, neuronal loss largely halts, producing a stable—but impaired—plateau.

 

Examples of biologically distinct subtypes currently grouped under “autism”

Condition / subtype Primary biological issue Timing of disruption Neuronal loss Developmental course What “repair” realistically means
CASK-related disorders Early cerebellar vulnerability; impaired synaptic and metabolic support (especially Purkinje cells) Prenatal / early infancy Yes, selective and early Early impairment → plateau Protection and optimization of remaining circuits
Rett syndrome (MECP2) Failure of activity-dependent maturation and gene regulation Infancy / early childhood Minimal true degeneration Regression → long-term stability Restoring plasticity conditions, not cell replacement
Mitochondrial disease with autistic features Energy failure during periods of high developmental demand Variable, often early Often selective Stress-related regression → relative stability Metabolic protection and stress reduction
Regressive autism (non-syndromic) Disrupted synaptic refinement under immune or metabolic stress Toddler years Usually no widespread loss Regression → plateau Stabilization and plasticity optimization
Mild / non-regressive autism Altered inhibitory balance, neuromodulation, network noise Early development, subtle No Lifelong, non-degenerative Optimization and tuning
Stroke (contrast) Acute focal neuronal loss in mature brain Adulthood Yes, focal Partial recovery Compensation and plasticity, not rebuilding
Dementia (contrast) Progressive neuronal loss and toxic protein accumulation Late adulthood Yes, progressive Ongoing decline Protection and slowing progression


 

Intervention strategies aligned with underlying biology

Biological context Primary therapeutic goal What helps most What has limited value Why this matters
CASK-related disorders Preserve remaining function Neuroprotection, metabolic support, seizure control, supportive therapies Neurogenesis-based repair narratives Early cell loss is irreversible
Rett syndrome Improve functional plasticity Neuromodulation, activity-dependent therapies, metabolic/redox support Structural repair strategies Neurons are present but constrained
Mitochondrial disease Reduce energetic stress Metabolic optimization, pacing, stress avoidance Forcing high-demand plasticity Energy limits learning capacity
Regressive autism Stabilize development Reducing excitotoxicity/inflammation, inhibitory balance, structured learning Assuming ongoing degeneration Regression ≠ progressive loss
Mild autism Network optimization Inhibitory tuning, sensory modulation, learning-based plasticity Repair or replacement framing Structure largely intact
Stroke Functional recovery Task-specific training, neuromodulation Expectation of neuronal replacement Compensation dominates
Dementia Slow decline Neuroprotection, risk reduction Plasticity-driven optimization Degeneration overwhelms repair


 

Core biological mechanisms and intervention logic

Core mechanism What goes wrong developmentally Downstream consequence Intervention logic (conceptual) Why timing matters
Excitatory–inhibitory imbalance Excess excitation or delayed inhibitory maturation Network noise, seizures, impaired synaptic refinement Improve inhibitory timing and reduce excessive excitation Early imbalance amplifies developmental stress
Calcium dysregulation Excess Ca²⁺ influx via NMDA and voltage-gated channels Mitochondrial overload, enzyme activation, cell injury Reduce excitotoxic stress and improve buffering capacity Developing neurons have limited calcium buffering
Mitochondrial dysfunction ATP production cannot meet developmental demand Energy collapse, impaired ion homeostasis Support mitochondrial function and reduce energy demand Energy failure during development causes irreversible loss
Oxidative stress ROS exceed immature antioxidant defenses Lipid, protein, and DNA damage Improve redox balance and reduce ROS generation Early oxidative damage compounds over time
Neuroinflammation Maladaptive cytokine signaling and glial activation Synaptic mis-pruning, excitotoxic amplification Dampen maladaptive inflammatory signaling Microglia are most influential during early refinement
Microglial dysregulation Abnormal synaptic pruning and immune signaling Long-term circuit instability Stabilize microglial state and timing Early pruning errors cannot be fully undone
Sleep and circadian disruption Reduced restorative and clearance processes Increased metabolic and oxidative stress Stabilize sleep–wake rhythms Sleep is critical for early brain resilience
Metabolic stress (systemic) Illness, fever, nutrient insufficiency Regression or stalled development Reduce cumulative physiological stress Repeated stress fixes lower developmental plateaus


An example - Phase 1 intervention in CASK: protection before optimization

In CASK-related disorders, early selective neuronal vulnerability—especially of Purkinje cells—imposes hard limits on later outcome.

A hypothetical Phase 1 approach does not aim to replace neurons or reconstruct development. Its goals are to:

  • Reduce excitotoxic and metabolic stress
  • Support mitochondrial and redox balance
  • Stabilize microglial behavior
  • Preserve remaining neuronal populations

My thinking suggested

  • NAC
  • Magnesium
  • Atorvastatin 
  • Pioglitazone or telmisartan
  • Verapamil

Phase 1 targets these upstream injury pathways simultaneously. N-acetylcysteine (NAC) Provides foundational redox protection by restoring glutathione, the brain’s primary antioxidant. This reduces oxidative damage, dampens inflammation, and indirectly limits excitotoxic injury. NAC has also been trialed in autism for irritability and agitation, consistent with reduced neuronal stress. Magnesium acts as an excitotoxicity buffer by modulating NMDA receptor activity and limiting pathological calcium influx. Magnesium supports network stability and sleep, and reduces calcium-driven mitochondrial injury. Verapamil complements magnesium by directly blocking L-type voltage-gated calcium channels, acting as a gatekeeper against intracellular calcium overload. This protects mitochondria, reduces neuronal hyperexcitability, and targets one of the fastest pathways to neuron injury. Atorvastatin is included for its pleiotropic anti-inflammatory effects, not lipid lowering. Statins suppress microglial activation, reduce pro-inflammatory cytokines, and improve endothelial and mitochondrial function—mechanisms relevant to chronic neuroinflammation observed in severe autism.  Pioglitazone or Telmisartan (PPAR-γ axis) targets metabolic-inflammatory signaling at the transcriptional level. Pioglitazone provides full PPAR-γ activation and has been trialed in autism, while telmisartan offers gentler, chronic partial PPAR-γ agonism with CNS penetration. This pathway suppresses microglial activation, improves mitochondrial efficiency, and reduces inflammation-driven excitotoxic vulnerability. 

Phase 1 is therefore protective, not reparative. By lowering early stress, it raises the ceiling for later optimization, even though it cannot undo early loss.


Can past critical periods be revisited?

Critical periods in brain development do not simply disappear; they are actively closed by inhibitory maturation, perineuronal nets, myelination, and epigenetic repression.

Early structural events—migration, layering, cell fate—cannot be replayed. What can be revisited, partially, are the rules governing plasticity. Improving inhibitory balance, metabolic support, and network stability can temporarily create a more permissive learning state.

This is functional reopening, not developmental replay.

 

A unifying perspective

Whether the brain can be repaired, protected, or optimized depends less on diagnostic labels and more on timing, cell loss, and the state of plasticity. Neuroblasts are crucial during construction, marginal during adult recovery, and largely irrelevant once degeneration becomes progressive.

In level 3 autism, early reduction of oxidative, inflammatory, microglial, and metabolic stress is likely to improve long-term outcome by preserving developmental capacity—even if it cannot entirely prevent disability. Later intervention remains valuable for fine-tuning within the biological constraints that remain.

 



14 comments:

  1. Hi Peter, Happy New Year!
    our pediatrician has said our son James can try ivermectin. He is 35kgs. Although the pediatrician is happy for him to try it, he does not not know what dose to start him on. Could you please let me know what dose of Ivermectin a 35kg boy should be taking? Are there any publications you would recommend our pediatrician to read? Thank you

    ReplyDelete
    Replies
    1. Ivermectin does have biological effects beyond its original use as an antiparasitic. However, its use became highly politicised during Covid, and as a result it is now regarded as a red-flag drug in many medical settings.

      Any off-label use in a child would need to be initiated, prescribed, and monitored by a physician who is willing to take full responsibility.

      There are many other inexpensive, repurposed drugs with genetic or mechanistic relevance to autism that have been formally studied, where dosing guidance and safety data are published in the peer-reviewed literature. In general, it is far more sensible to focus on those rather than on drugs surrounded by controversy and lacking autism-specific clinical evidence.

      Delete
    2. Ivermectin is used to help modulate nicotinic receptors a7nAChR. This is very beneficial in improvement of endothelial cells. Especially in pans/pandas flairs. Varenicline might be a better daily option though.

      Structural Elucidation of Ivermectin Binding to α7nAChR and the Induced Channel Desensitization

      https://pmc.ncbi.nlm.nih.gov/articles/PMC10020961/

      Delete
  2. Hello Peter !
    From the many pharmaceuticals I trialed and failed, Desmopressin still remains one that I see some sort of result from but it seems like it lacks the "power". Targeting ocytocin with l reuteri didn't help, vasopressin seems the answer in my case but besides desmopressin which activates v2a I don't have access to pure vasopressin nasal spray in uk..
    Balovaptan looks very interesting too, Telmisartan could be an alternative maybe?

    ReplyDelete
    Replies
    1. If desmopressin helps a bit, that does not necessarily point to a need for more vasopressin signaling. Desmopressin mainly acts on V2 receptors and its modest benefit is more likely coming from reduced background arousal or autonomic “noise” rather than direct social effects.

      Propranolol fits that same pattern more cleanly: it dampens noradrenergic over-activation, which can improve signal-to-noise in social and cognitive processing. In other words, it targets the downstream stress/arousal system that desmopressin may be indirectly helping, but in a more direct and better-studied way.

      So I would try Propranolol next. It is well studied in autism.

      Delete
    2. Thanks for your answer, Peter!

      I did trialed Propanolol, even Clonidine before getting to desmopressin with no success unfortunately. I noticed social communication comes more natural after desmopressin was used.

      Delete
    3. Are you using the nasal spray or the tablet form of desmopressin?

      You are not the first to see a better reaction than the literature would suggest.

      If you can get the liquid form of vasopressin, you could make a nasal spray. It does need to be refrigerated.

      Delete
    4. Using nasal spray form of desmopressin.

      I don't know where to get liquid form of vasopressin is something that can be found in the uk?

      Delete
    5. In the UK the liquid version is Argipressin 20 IU/ml Solution for Injection. This is prescription only.

      In the Stanford trials they just take the injectable version and make it into a nasal spray. Over there a compounding pharmacy does it.

      Delete
    6. Thank you I will look into it! Oversea delieveries with vasopressin you think might be risky since they will most likely be exposed to warm temperatures?

      Delete
    7. Ir is a clear issue. Best in the winter.

      Delete
  3. Hello Peter,

    In a recent study published it was reported that ASD brains have lower glutamate receptor (mglur5) availability, is this likely compensatory for high glutamate levels causing downregulation of these glutamate receptors you think? There are many possible things that could help this (like NAC, memantine or a modulator of the receptor itself) but nothing for sure was found in previous studies regarding it

    ReplyDelete
  4. Hello Peter, I’ve made myself a l.reuteri probiotic yogurt, which made me feel closer to others emotionally, more loving, but i still seem to not get a lot of social stuff, feel different from others, is there any medication/pharmaceuticals/treatments that could try? Thank you in advance

    ReplyDelete
    Replies
    1. Very many things can improve the situation with mild autism, but there is no one-size-fits-all solution. Some people stumble upon their solution by chance, like a lady who found an injection of a drug called Humira (that neutralizes a master inflammatory cytokine) was her silver bullet. Another reader who found his problems relate to mast cell issues and his solution is to use a sunbed (I did suggest a safer alternative)

      There are many people whose problems are actually in their guts and, when these are resolved, life gets better.

      Numerous drugs help in individual cases, such as:

      Low dose memantine
      Low dose aripiprazole
      Guanfacine
      Oxytocin (intranasal)
      Desmopressin (intranasal)
      Vasopressin (intranasal)
      Low dose Buspirone
      Low dose SSRI, like Prozac

      There are supplements, including

      L carnosine
      Creatine
      Taurine
      Magnesium threonate
      Citicoline (CDP-choline)

      It can take a long time to figure out what works in your own unique case. Often comorbid conditions provide clues, like autoimmune issues.

      Delete

Post a comment